National Institute of Health (NIH) Institutes, including the National Institute of Mental Health (NIMH), recently launched the Accelerating Medicines Partnership to advance promising therapies for those at risk of developing schizophrenia.
The partnership also includes multiple private and nonprofit organizations such as the American Psychiatric Association Foundation.
The partnership will invest $16.5 million over five years through the Foundation for the National Institutes of Health and brings together the NIH, the U.S. Food and Drug Administration (FDA), and academic, biopharmaceutical, life science, and nonprofit organizations.
Together these groups will define the early stages of risk, predict the likelihood of progression to psychosis as well as other outcomes, and will enable clinical trials to test new pharmacologic interventions.
The FDA will provide regulatory guidance on biological markers of disease progression, outcome measures, and endpoints for clinical trials.
NIMH plans to contribute $82.5 million to support three research projects: The ProNET: Psychosis-Risk Outcomes Network will map biomarkers onto a set of trajectories and outcomes; the Psychosis Risk Evaluation, Data Integration and Computational Technologies (PREDICT): Data Processing, Analysis, and Coordination Center will develop algorithms that can identify biomarkers predictive of outcomes; and Trajectories and Predictors in the Clinical High Risk for Psychosis Population: Australian Network of Clinics and International Partners will develop models that can predict clinical outcomes.